This invention provides a method for analyzing an analyte in a sample in a rapid and simple manner with high accuracy with the use of a sample of a mucosal fluid adhered to the mucosal surface of the nasal cavity collected using a nasal spray device in a less invasive and simple manner. The method comprises detecting an infectious disease by applying a washing liquid to the nasal cavity of a subject suspected of an infectious disease to wash the mucosal surface of the nasal cavity and using, as a sample, the collected wash liquid containing the mucosal fluid adhered to the mucosal surface of the nasal cavity.

A method of preparing a functionalized electrode array is provided. The method includes depositing a conductive material onto the surface of a substrate by droplet-based printing of particles comprising an electrically-conductive material. The surface of the conductive material is functionalized with a binding reagent that binds to an analyte. A three-dimensional electrode array and microfluidic test device are also provided.

The present invention pertains in the fields of antibody technology, protein engineering, medicine, pharmacology, infection biology, virology, and medical diagnostics. More specifically, the present disclosure provides VHH antibodies that prevent cell entry of and infection by SARS-CoV-2, a strategy for an enhanced block of the homotrimeric viral spike proteins by symmetry-matching VHH-fusions, implementations of this strategy, as well as VHH antibodies for sensitive detection of SARS-CoV2-infections.

An object of the present invention is to provide: a monoclonal antibody that makes it possible that adenovirus contained in a test specimen is detected and measured rapidly, simply, and with high-sensitivity; and an immunoassay for adenovirus and an immunoassay device therefor, for both of which the monoclonal antibody is used. The present invention provides: a monoclonal antibody or an antigen-binding fragment thereof, which undergoes antigen-antibody reaction with a hexon trimer of adenovirus; and an immunoassay and an immunoassay device that are used with the monoclonal antibody.

The present invention provides a device for detecting an analyte in a sample, including a chamber for receiving a testing element, where the testing element has a first position and a second position in the chamber; the testing element is not in contact with a fluid sample when the testing element is located in the first position, and the testing element is in contact with a fluid sample when the testing element is located in the second position.

The present invention pertains in the fields of antibody technology, protein engineering, medicine, pharmacology, infection biology, virology, and medical diagnostics. More specifically, the present disclosure provides VHH antibodies that prevent cell entry of and infection by SARS-CoV-2, a strategy for an enhanced block of the homotrimeric viral spike proteins by symmetry-matching VHH-fusions, implementations of this strategy, as well as VHH antibodies for sensitive detection of SARS-CoV2-infections.

Provided herein, in some aspects, are polypeptide monomers comprising an angiotensin-converting enzyme 2 (ACE2) ectodomain and an oligomerization domain. Also provided herein are oligomeric complexes comprising ACE2 monomers. Methods of using such to monomers and oligomeric complexes for the diagnosis, prevention, and treatment of viral infections such as the coronavirus are also provided.

A method and kit for detecting SARS-CoV-2 virus antigen present in an oropharyngeal lavage includes swishing and gargling a mouth rinse to distribute the same around the inside of the oral cavity and throughout an oropharyngeal space of the user. An absorbent end of a test stick is inserted into the oral cavity to collect liquid contents therefrom, the liquid contents including the mouth rinse and particles retrieved therefrom. The absorbent stick is removed and positioned vertically in a support stand while results are determined. Alternatively, the liquid contents are deposited from the oral cavity into a collection device, and the absorbent end of the test stick is inserted into the collection device and positioned vertically such that the test stick is retained in the collection device with the absorbent end of the test stick facing downwardly. An indicator on the test stick displays whether SARS-CoV-2 virus antigen is detected.

The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.

The present invention relates to a method of quantifying the amount of Mock Virus Particles (MVP) removed from a solution as a result of processing that solution through a purification technique. This method involves the steps of adding MVP to a solution, processing the solution through a purification technique, quantifying the amount of MVP removed from the solution. The present invention also relates to a kit that can be used in conjunction with the method. This kit will comprise at least one stock solution of MVP and at least one quantification solution.